Markets•2 reports
32DOOM SCORE
BioNTech shares fall 9% after colorectal cancer trial is discontinued
Germany
First seen: Aug 29, 2026, 8:31 AM UTCUpdated: Aug 29, 2026, 4:31 PM UTC
WHAT HAPPENED
BioNTech shares dropped 9% after the company discontinued a colorectal cancer program. The move represents a significant setback for the drug developer.
SO WHAT?
The trial halt could affect investor confidence and expectations for BioNTech's oncology pipeline.
FOR ME
Impact on Switzerland
Checking cached analysis...
MARKETS
Market impact
Checking cached analysis...
COVERAGE